Director/PDMR Shareholding

Apr 5, 2018

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 0350K
Advanced Medical Solutions Grp PLC
05 April 2018
 


 

5 April 2018

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 29 March 2018 that on the same day, Penny Freer, who is a Director, had sold 13,888 Ordinary Shares of 5p held in her name at a price of 318.60p per Ordinary Share. On the same day, Penny Freer also purchased 13,888 Ordinary Shares of 5p through a self-invested personal pension (“SIPP”) held in her name at a price of 318.80p per  Ordinary Share.

 

The number of shares held by Penny Freer and the beneficial ownership of the shares remains unchanged. Both transactions are part of normalised tax planning.

 

The transactions are summarised below:

 

Director

Number of Ordinary Shares sold from Penny Freer

Price per Ordinary Share sold

Number of Ordinary Shares purchased by SIPP

Price paid per Ordinary Share by SIPP

Penny Freer

13,888

318.60p

13,888

318.80p

 

Advanced Medical Solutions Group plc also announces that it was notified on 4 April 2018 that on the same day, Chris Meredith, who is a Director and PDMR, had sold 10,500 Ordinary Shares of 5p held in the name of Platform Securities Nominees Limited (“Nominee”) at a price of 310.20p per Ordinary Share.

 

On the same day, Chris Meredith purchased 2,568 Ordinary Shares of 5p through a self-invested personal pension (“SIPP”) held in his name at a price of 310.50p per Ordinary Share. The Company was also informed that at the same time Individual Savings Accounts (“ISA’s”) held in the name of Chris Meredith’s PCA’s purchased 4,095 Ordinary Shares of 5p at a price of 310.50p per Ordinary Share and that Lifetime Individual Savings Accounts (“LISA’s”) held in the name of Chris Meredith’s PCA’s purchased 3,837 Ordinary Shares of 5p at a price of 310.50p per Ordinary Share. 

 

The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and his PCA’s remains unchanged. These transactions are part of normalised tax planning.

 

The transactions are summarised below:

 

 

Director

Number of Ordinary Shares sold from Nominee

Price per Ordinary Share sold

Number of Ordinary Shares purchased by SIPP

Price paid per Ordinary Share by SIPP

Number of Ordinary Shares purchased by ISA’s

Price paid per Ordinary Share by ISA’s

Number of Ordinary Shares purchased by LISA’s

Price paid per Ordinary Share by LISA’s

Chris Meredith

2,568

310.20p

2,568

310.50p

Chris Meredith

4,095

310.20p

4,095

310.50p

Chris Meredith

3,837

310.20p

3,837

310.50p

 

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Penny Freer

2.

Reason for the notification

a)

Position/status: Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Sale of 13,888 Ordinary Shares of 5p held in the name of Penny Freer

·        Purchase of 13,888 Ordinary Shares of 5p by a SIPP held in the name of Penny Freer

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

Sale of shares from Penny Freer holding at 318.60p per share

13,888

Purchase by SIPP at 318.80p per share

13,888

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 13,888

Aggregated price: 318.60p

e)

Date of the transaction: 29/03/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Sale of 2,568 Ordinary Shares of 5p held in the name of the Nominee

·        Purchase of 2,568 Ordinary Shares of 5p by a SIPP held in the name of Chris Meredith

 

 

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

Sale of shares from Nominee holding at 310.20p per share

2,568

Purchase by SIPP at 310.50p per share

2,568

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 2,568

Aggregated price: 310.20p

e)

Date of the transaction: 04/04/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Sale of 4,095 Ordinary Shares of 5p held in the name of the Nominee

·        Purchase of 4,095 Ordinary Shares of 5p into ISA’s held in the name of Chris Meredith’s PCA’s

 

 

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

Sale of shares from Nominee holding at 310.20p per share

4,095

Purchase by ISA’s at 310.50p per share

4,095

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 4,095

Aggregated price: 310.20p

e)

Date of the transaction: 04/04/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Sale of 3,837 Ordinary Shares of 5p held in the name of the Nominee

·        Purchase of 3,837 Ordinary Shares of 5p into a LISA’s held in the name of Chris Meredith’s PCA’s

 

 

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

Sale of shares from Nominee holding at 310.20p per share

3,837

Purchase by LISA’s at 310.50p per share

3,837

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 3,837

Aggregated price: 310.20p

e)

Date of the transaction: 04/04/2018

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

End –

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Philippa Gardner

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Patrick Robb / Gary Clarence


 

About Advanced Medical Solutions Group plc see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 600 employees. .  For more information, please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHBLGDSUSGBGIU

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.